Perioperative pharmacokinetics of factor VII concentrate during liver surgery in a patient with congenital factor VII deficiency: an individual mathematical model

被引:7
作者
Charpiat, B
Laporte, S
Mismetti, P
Debize, G
Ducerf, C
机构
[1] Hop Croix Rousse, Hospices Civils Lyon, Dept Pharm, F-69317 Lyon, France
[2] Hop Croix Rousse, Hospices Civils Lyon, Dept Hematol, F-69317 Lyon, France
[3] Hop Croix Rousse, Hospices Civils Lyon, Surg & Liver Transplantat Unit, F-69317 Lyon, France
[4] Univ Hosp St Etienne, Clin Pharmacol Unit, Thrmbosis Res Grp, St Etienne, France
关键词
factor VII deficiency; liver surgery; pharmacokinetics; NONMEM;
D O I
10.1097/00001721-200207000-00011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A patient with congenital factor VII deficiency (baseline activity, 7%) underwent surgery for hepatocellular carcinoma. No literature reference was found concerning the management of this coagulation defect in patients requiring liver surgery. We report one such case, with special reference to the peri-operative management of factor VII replacement therapy and the pharmacokinetic behavior of factor VII. As a result of accidental suprahepatic vein lesion, a bleeding episode occurred. This was associated with an increase in factor VII clearance and volume of distribution values from 1.30 to 3.85 l/h, and from 6.51 to 13.2 l, respectively. After surgery, the patient continued to receive the concentrate every 8 h during the first nine post-operative days. No post-operative bleeding or thrombotic event was observed. The patient was discharged in good condition. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:457 / 460
页数:4
相关论文
共 10 条
  • [1] BEAL SL, 1992, NONMEM USERS GUIDES
  • [2] Berrettini M, 2001, HAEMATOLOGICA, V86, P640
  • [3] PROPHYLAXIS AND THERAPY WITH FACTOR-VII CONCENTRATE (HUMAN) IMMUNE, VAPOR HEATED IN PATIENTS WITH CONGENITAL FACTOR-VII DEFICIENCY - A SUMMARY OF CASE-REPORTS
    COHEN, LJ
    MCWILLIAMS, NB
    NEUBERG, R
    ZINKHAM, W
    BAUER, K
    GRIBBLE, TJ
    GLOWALLA, MB
    BORSON, R
    PHILLIPS, MD
    KUNSCHAK, M
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1995, 50 (04) : 269 - 276
  • [4] Girard P, 1998, THROMB HAEMOSTASIS, V80, P109
  • [5] Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors
    Ingerslev, J
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (04) : 425 - 432
  • [6] EVALUATION OF FACTOR-VIII PHARMACOKINETICS IN HEMOPHILIA-A SUBJECTS UNDERGOING SURGERY AND DESCRIPTION OF A NOMOGRAM FOR DOSING CALCULATIONS
    LONGO, G
    MESSORI, A
    MORFINI, M
    BAUDO, F
    CIAVARELLA, N
    CINOTTI, S
    FILIMBERTI, E
    GIUSTARINI, G
    MOLINARI, AC
    FERRINI, PR
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1989, 30 (03) : 140 - 149
  • [7] Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies
    Mariani, G
    Testa, MG
    Di Paolantonio, T
    Bech, RM
    Hedner, U
    [J]. VOX SANGUINIS, 1999, 77 (03) : 131 - 136
  • [8] Nzeako UC, 1996, AM J CLIN PATHOL, V105, P65
  • [9] Continuous infusion therapy in haemophilia
    Varon, D
    Martinowitz, U
    [J]. HAEMOPHILIA, 1998, 4 (04) : 431 - 435
  • [10] White B, 2000, BLOOD COAGUL FIBRIN, V11, P155